ReviewHeart failure reviews2021
Mechanisms underlying the pathophysiology of heart failure with preserved ejection fraction: the tip of the iceberg.
Review in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Short-Chain Fatty Acids in Heart Failure with Preserved Ejection Fraction: Pathophysiological Roles and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Circulating pro-angiogenic cells are preserved despite myocardial angiogenic signal deficits in HFpEF model.Scientific reports · 2026Article
- A perspective on the future of heart failure research.Journal of molecular and cellular cardiology plus · 2026Article
- Acute Heart Failure in Heart Failure with Preserved Ejection Fraction: A State-of-the-art Review from an International Expert Group.Cardiac failure review · 2026Review
- Angiotensin-Converting Enzyme Inhibitory Peptide Derived from UltrafineJournal of agricultural and food chemistry · 2025Article
- Changes in tumor and cardiac metabolism upon immune checkpoint.Basic research in cardiology · 2025Review
- Geniposide alleviates heart failure with preserved ejection fraction in mice by regulating cardiac oxidative stress via MMP2/SIRT1/GSK3β pathway.Acta pharmacologica Sinica · 2024Article
- Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction.ESC heart failure · 2023Article
- Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction.Heart failure reviews · 2023Review
- Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure.International journal of molecular sciences · 2023Review
- The Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies.Biomedicines · 2023Review
- Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study.ESC heart failure · 2023Article
- Systems Biology in Chronic Heart Failure-Identification of Potential miRNA Regulators.International journal of molecular sciences · 2022Article
- Non-invasive assessment of HFpEF in mouse models: current gaps and future directions.BMC medicine · 2022Article
- Mitochondrial CaInternational journal of molecular sciences · 2022Review
- HFpEF and Atrial Fibrillation: The Enigmatic Interplay of Dysmetabolism, Biomarkers, and Vascular Endothelial Dysfunction.Disease markers · 2022Article
- Mitochondrial bioenergetics and D-ribose in HFpEF: a brief narrative review.Annals of translational medicine · 2021Review
- Similarities and Differences Between HFmrEF and HFpEF.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with a complex aetiology often associated with several comorbidities, such as left ventricle pressure overload, diabetes mellitus, obesity, and kidney disease. Its pathophysiology remains obscure mainly due to the complex phenotype induced by all these associated comorbidities and to the scarcity of animal models that adequately mimic HFpEF. Increased oxidative stress, inflammation, and endothelial dysfunction are currently accepted as key players in HFpEF pathophysiology. However, we have just started to unveil HFpEF complexity and the role of calcium handling, energetic metabolism, and mitochondrial function remain to clarify. Indeed, the enlightenment of such cellular and molecular mechanisms represents an opportunity to develop novel therapeutic approaches and thus to improve HFpEF treatment options. In the last decades, the number of research groups dedicated to studying HFpEF has increased, denoting the importance and the magnitude achieved by this syndrome. In the current technological and web world, the amount of information is overwhelming, driving us not only to compile the most relevant information about the theme but also to explore beyond the tip of the iceberg. Thus, this review aims to encompass the most recent knowledge related to HFpEF or HFpEF-associated comorbidities, focusing mainly on myocardial metabolism, oxidative stress, and energetic pathways.
Indexed as
Identifiers
33411091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.